Treatment of antipsychotic-induced hyperprolactinemia: an umbrella review of systematic reviews and meta-analyses

• DOI: 10.3389/fpsyt.2024.1337274
• Publication Date: 2024-03-05T05:02:11Z
• Authors: Qitong Jiang; Tian Li; Lei Zhao; Yue Sun; Zhen Mao; Yujie Xing; Chuanyue Wang; Qijing Bo
• Keywords: Aripiprazole; PsycINFO

Background Hyperprolactinemia is a common antipsychotic-induced adverse event in psychiatric patients, and the quality of clinical studies investigating best treatments has varied. Thus, to better summarize evidence, we performed an umbrella review overlapping systematic reviews meta-analyses for treatment hyperprolactinemia. Methods The PubMed, Cochrane Library, PsycINFO, Scopus EMBASE were searched, meeting our inclusion criteria selected. Relevant data extracted, was conducted all included meta-analyses. assessed by using PRISMA scores AMSTAR 2 evaluation. Finally, evidence appropriate summarized discussed. Results Five published between 2013 2020 met requirements this review. ranged from 19.5–26. evaluation showed that 5 low 3 very quality. provide adding aripiprazole or dopamine agonist can effectively safely improve Two also adjunctive metformin reduce serum prolactin level, but more trials are needed confirm finding. Conclusion Adjunctive agonists have been proven be effective safe Among researched treatments, may most appropriate.